Biocon Limited (IN:BIOCON)
:BIOCON
Top Page
Biocon Limited
(BIOCON)
Select Model
Select Model
Rating:63Neutral
Price Target:
₹371.00
▲(1.87% Upside)
Action:ReiteratedDate:11/13/25
Biocon Limited's strong financial performance is the most significant factor contributing to its overall score, reflecting robust revenue growth and profitability. However, the technical analysis suggests caution due to overbought signals, and the high P/E ratio indicates potential overvaluation, which negatively impacts the overall score.
Positive Factors
Diversified revenue streams
Biocon's multi-pronged business model—biosimilars, complex generics, CDMO services and licensing—reduces single-product risk and smooths revenue volatility. Diverse cashflow sources support long-term investment in R&D, manufacturing scale and partner-led commercialization globally.
Negative Factors
Negative EPS growth
A near-28% decline in EPS signals pressure on per-share profitability that may reflect mix shifts, higher costs or one-offs. If sustained, falling EPS can constrain capital allocation, weaken returns to shareholders and reduce ability to self-fund expensive biologics development programs.
Read all positive and negative factors
Positive Factors
Negative Factors
Diversified revenue streams
Biocon's multi-pronged business model—biosimilars, complex generics, CDMO services and licensing—reduces single-product risk and smooths revenue volatility. Diverse cashflow sources support long-term investment in R&D, manufacturing scale and partner-led commercialization globally.
Read all positive factors
Biocon Limited (BIOCON) vs. iShares MSCI India ETF (INDA)
Market Cap
₹564.50B
Dividend Yield0.12%
Average Volume (3M)208.50K
Price to Earnings (P/E)91.6
Beta (1Y)0.99
Revenue Growth10.62%
EPS Growth-66.88%
CountryIN
Employees16,315
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)0.95
Shares Outstanding1,620,907,700
10 Day Avg. Volume177,351
30 Day Avg. Volume208,504
Financial Highlights & Ratios
PEG Ratio-38.08
Price to Book (P/B)1.88
Price to Sales (P/S)2.66
P/FCF Ratio23.64
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
₹435.00Price Target Upside19.44% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)9.11
Revenue Forecast (FY)₹202.41B
Biocon Limited Business Overview & Revenue Model
Company Description
Biocon Limited, a biopharmaceutical company, manufactures pharmaceuticals, and medicinal chemical and botanical products. The company operates through Generics, Novel Biologics, Biosimilars, and Research Services segments. It focuses in the areas ...
How the Company Makes Money
Biocon makes money primarily by selling pharmaceutical products and related services across a few major revenue streams. (1) Biosimilars and biologics: A significant portion of earnings comes from developing and manufacturing biosimilar versions o...
Biocon Limited Financial Statement Overview
Summary
Income Statement
82
Very Positive
Balance Sheet
78
Positive
Cash Flow
75
Positive
| Breakdown | TTM | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 164.43B | 152.62B | 147.56B | 111.74B | 81.84B | 71.43B |
| Gross Profit | 98.38B | 92.44B | 91.73B | 69.62B | 50.11B | 48.99B |
| EBITDA | 34.13B | 31.24B | 32.71B | 26.57B | 19.56B | 16.52B |
| Net Income | 4.86B | 10.13B | 10.22B | 4.63B | 6.48B | 7.41B |
Balance Sheet | ||||||
| Total Assets | 627.60B | 587.97B | 560.71B | 520.43B | 203.94B | 185.22B |
| Cash, Cash Equivalents and Short-Term Investments | 64.69B | 49.24B | 25.74B | 37.26B | 29.65B | 32.24B |
| Total Debt | 165.35B | 183.62B | 162.77B | 180.19B | 51.47B | 44.81B |
| Total Liabilities | 297.05B | 310.85B | 307.96B | 295.54B | 109.24B | 100.15B |
| Stockholders Equity | 268.04B | 216.44B | 197.84B | 178.67B | 84.33B | 76.27B |
Cash Flow | ||||||
| Free Cash Flow | -575.00M | 17.18B | 10.22B | 1.26B | -7.48B | -5.87B |
| Operating Cash Flow | 8.03B | 40.61B | 29.54B | 18.52B | 11.77B | 11.60B |
| Investing Cash Flow | -12.76B | -2.34B | -10.04B | -142.82B | -16.99B | -36.25B |
| Financing Cash Flow | 14.03B | -18.54B | -23.33B | 130.49B | 2.42B | 25.64B |
Biocon Limited Technical Analysis
Negative
364.20
Price Trends
374.37
Negative
381.98
Negative
374.33
Negative
Market Momentum
-9.62
Positive
37.79
Neutral
21.49
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:BIOCON, the sentiment is Negative. The current price of 364.2 is below the 20-day moving average (MA) of 365.57, below the 50-day MA of 374.37, and below the 200-day MA of 374.33, indicating a bearish trend. The MACD of -9.62 indicates Positive momentum. The RSI at 37.79 is Neutral, neither overbought nor oversold. The STOCH value of 21.49 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:BIOCON.
Biocon Limited Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
66 Neutral | ₹111.09B | 54.58 | ― | 0.80% | 3.63% | -1.21% | |
65 Neutral | ₹70.65B | 57.24 | ― | 0.22% | 63.34% | 109.89% | |
63 Neutral | ₹564.50B | 91.56 | ― | 0.12% | 10.62% | -66.88% | |
61 Neutral | ₹103.31B | 59.25 | ― | 0.74% | 3.80% | 64.94% | |
61 Neutral | ₹163.09B | 439.86 | ― | 0.19% | 8.57% | -2.93% | |
55 Neutral | ₹194.20B | -41.77 | ― | 0.08% | 2.66% | -153.15% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
IN:BIOCON
Biocon Limited
344.95
16.09
4.89%
IN:BLUEJET
Blue Jet Healthcare Limited
402.60
-333.11
-45.28%
IN:CONCORDBIO
Concord Biotech Ltd.
1,046.60
-674.84
-39.20%
IN:JUBLINGREA
Jubilant Ingrevia Ltd.
641.50
-20.41
-3.08%
IN:PPLPHARMA
Piramal Pharma Limited
146.50
-75.90
-34.13%
IN:SYNGENE
Syngene International Ltd.
402.95
-318.15
-44.12%
Biocon Limited Corporate Events
Biocon Plans Investor Meetings in Hong Kong and Singapore
Apr 7, 2026
Biocon Limited has scheduled a series of in-person investor engagements in Asia, including participation in the HSBC Global Investment Summit 2026 in Hong Kong on April 14–15 and an investor roadshow in Singapore on April 16–17, featur...
Biocon Overhauls Top Management as It Integrates Biocon Biologics
Mar 27, 2026
Biocon’s board has approved a significant reshaping of its leadership as part of its ongoing integration with Biocon Biologics, accepting the resignation of CEO and Managing Director Siddharth Mittal and interim CFO Mukesh Kamath, both of wh...
Biocon Reshapes Top Management as Biocon Biologics Integration Deepens
Mar 27, 2026
Biocon’s board has approved a major leadership reshuffle as part of its ongoing integration with Biocon Biologics, including the resignation of CEO and Managing Director Siddharth Mittal, effective March 31, 2026, as he moves to another role...
Biocon Overhauls Top Management as It Integrates Biocon Biologics
Mar 27, 2026
Biocon’s board has approved a major reshaping of its leadership as part of the ongoing integration of Biocon Biologics to create a unified biopharmaceutical group. Chief Executive Officer and Managing Director Siddharth Mittal will step down...
Biocon Overhauls Top Management as Biocon Biologics Integration Deepens
Mar 27, 2026
Biocon’s board has approved a major reshaping of its top leadership as part of its ongoing integration with Biocon Biologics to create a unified global biopharmaceutical business. The company accepted the resignation of CEO and Managing Dire...
Biocon Names Shreehas Tambe CEO as Integrated Biopharma Platform Takes Shape
Mar 27, 2026
Biocon Limited has appointed Shreehas Tambe as Chief Executive Officer and Managing Director effective April 1, 2026, making him the first CEO of the newly integrated Biocon spanning biosimilars and generics. The company has also named Kedar Upadh...
Biocon to Join JP Morgan India Credit Investor Trip in Virtual Meeting
Mar 5, 2026
Biocon Limited has informed the stock exchanges that its management will participate in JP Morgan’s annual flagship India Credit Investor Trip on March 11, 2026, via a virtual group interaction. The company emphasized that no unpublished pri...
Biocon bolsters pharma subsidiaries with fresh preference share funding
Mar 3, 2026
Biocon has injected fresh capital into its wholly owned subsidiaries Biocon Biosphere and Biocon Pharma by acquiring large tranches of optionally convertible redeemable non-cumulative preference shares in each entity. The funding is aimed at meeti...
Biocon Publishes Investor Presentation Ahead of Analyst Meets
Feb 25, 2026
Biocon Limited has notified stock exchanges that it has prepared an investor presentation for meetings with analysts and institutional investors scheduled on February 25 and 26, 2026. The materials, shared under regulatory disclosure norms, will a...
Biocon Raises Rs 4,150 Crore via QIP to Fully Acquire Biocon Biologics
Jan 15, 2026
Biocon Limited has raised Rs 4,150 crore (approximately USD 460 million) via a Qualified Institutions Placement, issuing over 112.6 million equity shares at Rs 368.35 each to a broad base of domestic and international institutional investors, incl...
Biocon Raises ₹41.5 Billion via Qualified Institutions Placement, Expands Equity Base
Jan 14, 2026
Biocon Limited has raised approximately ₹41,500 million through a Qualified Institutions Placement (QIP), issuing 112,664,585 new equity shares of face value ₹5 each at an issue price of ₹368.35 per share to eligible qualified in...
Biocon Raises ₹41.5 Billion via QIP, Expands Equity Base
Jan 14, 2026
Biocon Limited has raised approximately ₹41,500 million through a qualified institutions placement (QIP) of 11,26,64,585 equity shares at an issue price of ₹368.35 per share, including a premium of ₹363.35. The fundraising, appro...
Biocon Closes QIP, Raises Capital Through Discounted Share Allocation
Jan 14, 2026
Biocon Limited has closed its Qualified Institutions Placement (QIP) of equity shares, initiated on January 12, 2026, after receiving applications and funds from eligible qualified institutional buyers. The company’s Fund Raising Committee a...
Biocon Clears Placement Document for Qualified Institutions Share Issue
Jan 14, 2026
Biocon Limited has approved and adopted a placement document for a Qualified Institutions Placement (QIP) of equity shares with a face value of ₹5 each, in line with SEBI’s Issue of Capital and Disclosure Requirements Regulations and r...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.